Subscribe to RSS
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.4103/ijmpo.ijmpo_62_18
Chemotherapy Toxicity in Elderly Population ≥65 Years: A Tertiary Care Hospital Experience from India
Financial support and sponsorship Nil.![](https://www.thieme-connect.de/media/10.1055-s-00050348/201904/lookinside/thumbnails/10-4103-ijmpo-ijmpo_62_18_531-1.jpg)
Abstract
Context: Trials in the elderly have established that older individuals may benefit from chemotherapy to the same extent as younger individuals. Although the elderly patient is a prototype for cancer, very few clinical trials focus on the therapeutic decisions most directly facing older adults. Aims: This study was undertaken to study the chemotherapy-induced severe toxicity among elderly. Settings and Design: This study was a prospective, observational cohort study. The study commenced in October 2014 after obtaining clearance from the hospital ethics and protocol committee. Subjects and Methods: A total of 100 patients were included in the study. All patients were of age ≥65 years, had malignancy, and were planned to start with chemotherapy. Development of Grade 3/4/5 nonhematologic (NH) or Grade 4/5 hematologic (H) toxicities was taken as the development of severe toxicity. Statistical Analysis Used: The quantitative variables were expressed as a mean ± standard deviation and compared using unpaired t-test. P < 0.05 was considered statistically significant. Results: Overall, 64 (64%) patients were able to complete their prescribed treatment. Forty-four patients (44%) of our study cohort experienced Grade 4 H or Grade 3/4 NH toxicity. The most common H Grade 4 toxicities were neutropenia (6%) and thrombocytopenia (5%). The most common NH toxicities were fatigue (18%), infection (10%), and cardiac abnormalities (4%). Conclusions: Less than 50% of elderly patients experience severe chemotherapy-related toxicity. First 30 days are most important for toxicity assessment as 45% of patients experienced toxicity in this time frame.
Publication History
Received: 17 March 2018
Accepted: 21 June 2018
Article published online:
03 June 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Lipsitz LA. Physiological complexity, aging, and the path to frailty. Sci Aging Knowledge Environ 2004; 2004: pe16
- 2 Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M. et al., (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, SEER data submission, posted to the SEER web site, April 2018. Available from: https://seer.cancer.gov/csr/1975_2015/. [Last based on 2017 Nov 05]
- 3 Parry C, Kent EE, Mariotto AB, Alfano CM, Rowland JH. Cancer survivors: A booming population. Cancer Epidemiol Biomarkers Prev 2011; 20: 1996-2005
- 4 Paola S. India’s Aging Population. Population Reference Bureau; March 2012
- 5 Arokiasamy P, Bloom D, Lee J, Feeney K, Ozolins M. Longitudinal aging study in India: Vision, design, implementation, and some early results. In: Smith JP, Majmundar M. editors Aging in Asia: Findings From New and Emerging Data Initiatives. Washington (DC): National Academies Press (US); 2012
- 6 Carreca I, Balducci L, Extermann M. Cancer in the older person. Cancer Treat Rev 2005; 31: 380-402
- 7 Zinzani PL, Storti S, Zaccaria A, Moretti L, Magagnoli M, Pavone E. et al. Elderly aggressive-histology non-Hodgkin’s lymphoma:First-line VNCOP-B regimen experience on 350 patients. Blood 1999; 94: 33-8
- 8 Gómez H, Mas L, Casanova L, Pen DL, Santillana S, Valdivia S. et al. Elderly patients with aggressive non-Hodgkin’s lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998; 16: 2352-8
- 9 Sonneveld P, de Ridder M, van der Lelie H, Nieuwenhuis K, Schouten H, Mulder A. et al. Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin’s lymphoma using CHOP versus CNOP chemotherapy. J Clin Oncol 1995; 13: 2530-9
- 10 O’Reilly SE, Connors JM, Howdle S, Hoskins P, Klasa R, Klimo P. et al. In search of an optimal regimen for elderly patients with advanced-stage diffuse large-cell lymphoma: Results of a phase II study of P/DOCE chemotherapy. J Clin Oncol 1993; 11: 2250-7
- 11 Hutchins LF, Unger JM, Crowley JJ, Coltman Jr. CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-7
- 12 Parikh PM, Bakshi AV. Cancer in the elderly – Get ready for the ’epidemic’. In: Gupta SB. editor API Medicine Update. Vol. 15. Association of Physicians of India. Mumbai: Printed by Jaypee brothers medical Publishers (P) Ltd; 2005
- 13 Agarwal SP, Rao YN, Gupta S. National Cancer control Program (NCCP). Fifty Years of Cancer Control in India. 1st ed. Ministry of Health and Family Welfare. GOI; 2002
- 14 Sargent DJ, Goldberg RM, Jacobson SD, Macdonald JS, Labianca R, Haller DG. et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-7
- 15 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M. et al. GLOBOCAN 2012 v 1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://www.globocan.iarc.fr. [Last accessed on 2016 Dec 26]
- 16 Patil VM, Chakraborty S, Dessai S, Kumar SS, Ratheesan K, Bindu T. et al. Patterns of care in geriatric cancer patients - an audit from a rural based hospital cancer registry in Kerala. Indian J Cancer 2015; 52: 157-61
- 17 Goyal LK, Jasuja SK, Meena H, Hooda L, Hasan SI, Agrawal D. Cancer in Geriatric patients: A single center observational study. Sch J App Med Sci 2016; 4: 1781-5
- 18 Sarkar A, Shahi U. Assessment of cancer care in Indian elderly cancer patients: A single center study. South Asian J Cancer 2013; 2: 202-8
- 19 Freyer G, Geay JF, Touzet S, Provencal J, Weber B, Jacquin JP. et al. Comprehensive geriatric assessment predicts tolerance to chemotherapy and survival in elderly patients with advanced ovarian carcinoma: A GINECO study. Ann Oncol 2005; 16: 1795-800
- 20 Extermann M, Boler I, Reich RR, Lyman GH, Brown RH, DeFelice J. et al. Predicting the risk of chemotherapy toxicity in older patients: The chemotherapy risk assessment scale for high-age patients (CRASH) score. Cancer 2012; 118: 3377-86
- 21 Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP. et al. Predicting chemotherapy toxicity in older adults with cancer: A prospective multicenter study. J Clin Oncol 2011; 29: 3457-65
- 22 Hurria A, Mohile S, Gajra A, Klepin H, Muss H, Chapman A. et al. Validation of a prediction tool for chemotherapy toxicity in older adults with cancer. J Clin Oncol 2016; 34: 2366-71
- 23 Crawford J, Dale DC, Kuderer NM, Culakova E, Poniewierski MS, Wolff D. et al. Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: The results of a prospective nationwide study of oncology practice. J Natl Compr Canc Netw 2008; 6: 109-18
- 24 Lyman GH, Morrison VA, Dale DC, Crawford J, Delgado DJ, Fridman M. et al. Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin’s lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003; 44: 2069-76